Display Settings:

Format

Send to:

Choose Destination
    J Neurooncol. 2010 May;97(3):389-92. Epub 2009 Oct 20.

    Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.

    Source

    Division of Clinical Neurooncology, Department of Neurology, University of Bonn, Sigmund-Freud-Str 25, 53105 Bonn, Germany.

    Abstract

    This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities. In 17 patients (62-90 years old), the complete response rate was 47%, median progression-free survival was 5 months, and median overall survival was 21 months. Five of 17 patients (29.4%) had prolonged responses for at least 12 months and survived for more than 24 months. Three of these patients had a methylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter, while the MGMT status was not assessable in the remaining two patients. Temozolomide monotherapy appears to be effective in a subgroup of elderly PCNSL patients and deserves further evaluation.

    PMID:
    19841864
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk